The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
NEW YORK – Roche will share with regulators data from a Phase III trial of its KRAS G12C inhibitor divarasib, showing its ability to keep lung cancer patients alive longer without progression compared ...
NEW YORK – The US Food and Drug Administration on Wednesday said it has expanded the approval for Vertex Pharmaceuticals' gene-editing drug Casgevy (exagamglogene autotemcel) to include patients as ...
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
NEW YORK – The European Commission has approved Novartis' gene therapy Itvisma (onasemnogene abeparvovec) for patients at least two years old with 5q-associated spinal muscular atrophy (SMA) and ...
NEW YORK – The earliest CAR T-cell therapies are starting to hit decade milestones, and despite their success, their developers say it's worth it to keep asking questions about safety and efficacy.
NEW YORK – Natera's circulating tumor DNA (ctDNA) test Signatera will be used to measure minimal residual disease in Aveta Biomics' Phase III trial of an immunotherapy for locally advanced head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results